FDA Submits Interim Peptide Compounding Policy for White House Review: What Pharmacies Should Know
Overview of the Regulatory Action According to a client alert from the law firm Buchanan Ingersoll & Rooney PC, the U.S.
Read Full ArticleAll News
Pharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026
Pharmacists Must Guide Peptide Talks Pending FDA Action, NCPA 2026 Session Signals Pharmacists are being urged to take a proactive role in counseling patients on peptide therapies even as the Food and Drug Administration continues to weigh how it will regulate this fast-growing category of compound...
Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients
Houston Compounding Pharmacy Faces Scrutiny After FDA Finds 14 Violations Tied to Recalled Tirzepatide Vials A Houston-based compounding pharmacy linked to a recall of compounded tirzepatide injectable vials was cited by the U.S.
US FDA takes step to change peptide compounding policy
Overview of the Regulatory Action Reuters has reported that the U.S. Food and Drug Administration is moving to revise its policy governing the compounding of peptide drugs, a category of therapeutics that has exploded in popularity and regulatory scrutiny over the past several years.
FDA Peptide Compounding Policy: What a Temporary Enforcement Reprieve Could Mean for Pharmacies
Overview of the Regulatory Action The compounding pharmacy industry received notable, if temporary, relief in a recent regulatory development concerning peptide products, as reported by law firm Buchanan Ingersoll & Rooney PC. According to the firm's analysis, the U.S.
fda approved peptide drugs for weight loss 2026
FDA's Peptide Weight-Loss Pipeline Faces Scrutiny as 2026 Approvals Loom Regulatory attention on peptide-based weight-loss drugs is intensifying as the pharmaceutical industry anticipates a new wave of potential FDA approvals in 2026.
FDA Recalls and Warnings: Sterility Issues With Compounded GLP-1s, Foreign Pills in Generic Reglan Bottles
FDA Recalls and Warnings: Sterility Issues With Compounded GLP-1s, Foreign Pills in Generic Reglan Bottles The U.S.
Pharmacy Law Lowdown: FDA’s Evaluation of Peptides
Pharmacy Law Lowdown: FDA's Evaluation of Peptides The U.S. Food and Drug Administration's ongoing scrutiny of peptide products is once again in the spotlight, following a report published by Drug Topics under its "Pharmacy Law Lowdown" series examining the agency's evaluation of peptides.
The FDA Is Struggling To Police The Peptide Boom
The FDA Is Struggling To Police The Peptide Boom The Food and Drug Administration is facing mounting difficulty controlling the rapid proliferation of therapeutic and performance-enhancing peptides flooding the American marketplace, according to a Forbes report examining the agency's regulatory gap...
FDA warns about some peptide injections possibly linked to illnesses
FDA Warns About Some Peptide Injections Possibly Linked to Illnesses The U.S. Food and Drug Administration has issued a warning regarding certain peptide injections that may be associated with reported illnesses, according to a report from NBC News.
FDA Warning Letter to Empower Pharmacy and What It Means for 503A Compounding Pharmacies
FDA Warning Letter to Empower Pharmacy Signals Heightened Scrutiny of 503A Compounders The U.S. Food and Drug Administration has issued a warning letter to Empower Pharmacy, one of the nation's largest compounding pharmacies, according to reporting from the law firm Buchanan Ingersoll & Rooney PC.
FDA Recalls and Warnings: Glutathione Peptide Injections Recalled Over Endotoxin Contamination
FDA Recalls and Warnings: Glutathione Peptide Injections Recalled Over Endotoxin Contamination Federal regulators have flagged injectable glutathione products for endotoxin contamination, according to a report from MedShadow.
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
Overview of the Regulatory Action A recent Food and Drug Administration advisory panel vote has reignited debate over how the agency should regulate the rapidly growing category of therapeutic peptides, according to a report from AJMC (American Journal of Managed Care).
China's Shengnuo Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended
China's Shengnuo Subsidiary Hit with FDA Import Ban, All Peptide API Sales to US Suspended The U.S.
Federal regulators and state boards crack down on RUO peptides
Federal and State Regulators Intensify Scrutiny of "Research Use Only" Peptides Federal agencies and state licensing boards are ramping up enforcement against the sale and clinical use of "research use only" (RUO) peptides, a category of compounds that has proliferated in wellness clinics, teleheal...
Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs? Here's what to know.
FDA Crackdown on Compounded GLP-1 Drugs Raises Access and Affordability Concerns The Food and Drug Administration's ongoing enforcement actions against compounded versions of popular GLP-1 weight-loss medications are raising new questions about whether millions of Americans will lose access to lowe...
‘Peptide Party’ in Bengaluru cancelled after FDA raises regulatory, safety concerns
‘Peptide Party’ Event in Bengaluru Called Off Amid FDA Scrutiny A gathering billed as a “Peptide Party” scheduled to take place in Bengaluru has been cancelled after regulatory and safety concerns were raised, according to a report from The New Indian Express.
The Best FDA Decision On Peptide Authorization Isn’t Yes Or No
The Best FDA Decision On Peptide Authorization Isn't Yes Or No The Food and Drug Administration's approach to regulating therapeutic peptides has reached an inflection point, and according to a recent analysis published by Forbes, the most consequential path forward for the agency may not be a simp...
Phoenix doctor urges caution as FDA moves to regulate popular peptides
Phoenix Doctor Urges Caution as FDA Moves to Regulate Popular Peptides A Phoenix-based physician is warning consumers to exercise caution amid growing regulatory scrutiny of peptide therapies, as the U.S.
FDA issues warning letters to five unapproved GLP-1 websites
FDA Issues Warning Letters to Five Unapproved GLP-1 Websites The U.S. Food and Drug Administration has issued warning letters to five websites for allegedly marketing unapproved versions of GLP-1 receptor agonist products, according to a report from pharmaphorum.com.
FDA cracks down on online black market for weight loss peptides
FDA Targets Illicit Online Sales of Weight Loss Peptides Amid Surging Demand The U.S. Food and Drug Administration is intensifying scrutiny of an expanding online black market for weight loss peptides, according to a report from Pharmaceutical Technology.